REG - BSF Enterprise PLC - 3D Bio-Tissues partners with cell growth company

BSF EnterpriseAnnouncement

23/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221123:nRSW2805Ha&default-theme=true

RNS Number : 2805H  BSF Enterprise PLC  23 November 2022

 23 November 2022

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues enters partnership with leading cell growth company

 

BSF (LSE:BSFA), an investment company focused on unlocking the next generation
of biotech solutions and the development of lab-grown tissues, is pleased to
announce that its 100% owned subsidiary, 3D Bio-Tissues Ltd (3DBT), is to
partner with the growth factor company Qkine to help accelerate the creation
of affordable cultivated meat.

 

Together, 3DBT and Qkine will work to optimise the effectiveness of
animal-free cultures to reduce the dependence on other protein compounds,
increase yields, and lower overall costs. This is expected to pave the way for
advances in cellular agriculture in the UK and world-wide.

 

The collaboration will see 3DBT combine City-mix™, its animal free media
supplement for culturing muscle and fat cells, with Qkine's growth enabling
protein engineering technology.  Qkine's technology aids the growth of stem
cell culture protocols, while 3DBT's innovative macromolecular crowding
technology enhances the speed of development of protein components in culture
media. Together these can help reduce the production time and costs for
growing cultivated meat, making it more accessible and affordable to a growing
mass production market.

 

The announcement comes just days after the U.S. Food and Drug Administration
(FDA) approved lab-grown meat for consumption for the first time, in relation
to Upside Foods cultivated chicken. In November 2022, 3DBT also announced that
it had successfully produced three small prototype fillets of cultivated meat.
3DBT now plans to unveil further larger scale prototypes and the UK's first
100% lab-grown fillet in the coming months.

Dr. Catherine Elton, CEO of Qkine commented: "We are delighted to be working
with the innovative 3D Bio-Tissues team. Qkine is committed to establishing a
UK-based supply chain for the cellular agriculture industry and contributing
to building a more sustainable global future food system."

Che Connon, Chief Executive of 3D-Bio Tissues, said: "We look forward to
partnering with Qkine, which has long been at the forefront of developing
high-quality protein growth factors for research applications. Our mission is
to accelerate the creation of affordable cultivated meat and we strongly
believe combining 3DBT's unique food-grade City-mix™ supplements with
Qkine's world-leading products can provide great strides toward reaching this
goal, putting us on the path to a sustainable cultivated meat industry."

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                             0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882

 Elisabeth Cowell                        BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues Ltd (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

About Qkine

Qkine manufactures high-purity, animal-free growth factors, cytokines and
other complex proteins. Based in Cambridge, UK, Qkine combines proprietary
production processes with protein engineering technology to tackle fundamental
biological and scalability challenges for the fast-growing stem cell,
organoid, regenerative medicine, and cultured meat sectors. Contact the Qkine
team at proteins@qkine.com for more information.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDDBDBXGDDGDD